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Abstract. 
 
Migratory cells including invasive tumor cells
frequently express CD44, a major receptor for hyaluro-
nan and membrane-type 1 matrix metalloproteinase
(MT1-MMP) that degrades extracellular matrix at the
pericellular region. In this study, we demonstrate that
MT1-MMP acts as a processing enzyme for CD44H, re-
leasing it into the medium as a soluble 70-kD fragment.
Furthermore, this processing event stimulates cell motil-
ity; however, expression of either CD44H or MT1-MMP
 
alone did not stimulate cell motility. Coexpression of
MT1-MMP and mutant CD44H lacking the MT1-
MMP–processing site did not result in shedding and did
not promote cell migration, suggesting that the process-
 
ing of CD44H by MT1-MMP is critical in the migra-
tory stimulation. Moreover, expression of the mutant
CD44H inhibited the cell migration promoted by
CD44H and MT1-MMP in a dominant-negative man-
ner. The pancreatic tumor cell line, MIA PaCa-2, was
found to shed the 70-kD CD44H fragment in a MT1-
MMP–dependent manner. Expression of the mutant
CD44H in the cells as well as MMP inhibitor treatment
effectively inhibited the migration, suggesting that MIA
PaCa-2 cells indeed use the CD44H and MT1-MMP as
migratory devices. These ﬁndings revealed a novel in-
teraction of the two molecules that have each been im-
plicated in tumor cell migration and invasion.
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Introduction
 
CD44 is a multistructual and multifunctional cell adhesion
molecule that is involved in cell–cell and cell–matrix inter-
actions (Naot et al., 1997). This family of glycoprotein con-
sists with many isoforms generated by both posttransla-
tional modifications and different use of alternatively
spliced exons. The encoded amino acids from variant ex-
ons are inserted within the extracellular part between
ligand binding globular domain and transmembrane do-
 
main (Naot et al., 1997). To date, at least 20 differ-
ent CD44 transcripts have been described. However, the
most abundant form is the standard hematopoietic type,
CD44H, which does not have any variant insertions (Naot
et al., 1997).
 
Its adhesion activity to extracellular matrix (ECM)
 
1
 
 was
shown to be located in the NH
 
2
 
-terminal globular domain
that contains three disulfide bonds. Through this domain,
CD44 binds hyaluronic acid (HA), type I collagen, fi-
bronectin, fibrin, laminin, and chondroitin sulfate (Naot et
al., 1997). CD44 has been shown to play roles in many im-
portant physiological and pathological processes such as
lymphocyte homing, T cell activation, wound healing, an-
giogenesis, and metastatic spread of cancer cells (Naot et
al., 1997). It is expressed in many types of migratory cells
and metastatic tumor cells (Gunthert et al., 1991; Naot et
al., 1997; Sneath and Mangham, 1998) and has been shown
to promote miratory potential of these cells (Thomas et
al., 1992, 1993; Henke et al., 1996; Okada et al., 1996; Tro-
chon et al., 1996; Ladeda et al., 1998). However, the mech-
anism underlying the phenomenon is not clear.
CD44 was shown to be shed from the cell surface by
proteolytic processing (Goebeler et al., 1996; Naot et al.,
1997; Okamoto et al., 1999). The soluble CD44 (sCD44)
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has been detected in cell culture supernatants (Goebeler
et al., 1996; Okamoto et al., 1999), arthritic synovial fluid
(Haynes et al., 1991), and plasma (Haberhauer et al., 1997;
Kittl et al., 1997). Also, it has been reported that higher
levels of sCD44 were detected in serum from the patients
bearing malignant cancer with metastasis (Guo et al., 1994;
Masson et al., 1999; Yamane et al., 1999). Thus, generation
of sCD44 may reflect certain biological and pathological
situations. The shedding was shown to be inhibited by the
inhibitors specific for metalloproteinases or serine pro-
teinases (Bazil and Strominger, 1994; Okamoto et al.,
1999). Recently, inhibition of metalloproteinase but not of
serine proteinase was demonstrated to suppress CD44-
dependent cell migration (Okamoto et al., 1999), suggest-
ing that CD44-mediated cell migration may require the
cell surface processing of CD44 by metalloproteinase.
However, the proteinase responsible for the shedding is
not identified yet.
When cells migrate in the tissue, ECM located at the mi-
gratory direction has to be degraded. Matrix metallopro-
teinases (MMPs) are a group of the enzymes that is re-
sponsible for ECM degradation (Werb, 1997; Matrisian,
1999; Murphy and Gavrilovic, 1999; Nagase and Woess-
ner, 1999). To date, 21 mammalian MMP genes were mo-
lecularly cloned, and their products can be subgrouped
into the soluble-type MMPs and the membrane-type
MMPs (MT-MMPs) (Nagase and Woessner, 1999; Seiki,
1999). Since MT-MMPs are tethered to the plasma mem-
brane either through transmembrane domain (Sato et al.,
1994; Cao et al., 1995) or glycosylphosphatidylinositol an-
chor (Itoh et al., 1999; Kojima et al., 2000), they are well
placed for pericellular proteolysis that associates with cell
growth, migration, and morphological change of cells in
tissue (Nagase and Woessner, 1999; Seiki, 1999). They
have a basic amino acid motif at the end of propeptide that
can be recognized and processed by furin or related pro-
teinase for the activation (Nagase and Woessner, 1999;
Seiki, 1999; Yana and Weiss, 2000). Thus, they are pro-
cessed intracellularly and appear on the cell surface as an
active form.
Among the MT-MMPs, MT1-MMP is shown to be fre-
quently expressed in migratory cells such as macrophages
(Sato et al., 1997), endothelial cells (Hiraoka et al., 1998),
and invasive cancer cells (Seiki, 1999). MT1-MMP de-
grades collagen types I, II, and III, fibronectin, laminin 1
and 5, vitronectin, and aggrecan (d’Ortho et al., 1997;
Ohuchi et al., 1997; Buttner et al., 1998; Fosang et al., 1998;
Koshikawa et al., 2000). It also activates other MMPs such
as proMMP-2 (gelatinase A) (Sato et al., 1994) and
proMMP-13 (procollagenase 3) (Knauper et al., 1996).
Thus, the expression of MT1-MMP on the cell surface is
thought to trigger multiple proteinase cascades.
Although the investigations of MT-MMPs have been fo-
cused on ECM degradation, it is possible that they also
process membrane proteins. Cell surface localization of
MT1-MMP, as well as CD44, was reported to be at the
edge of the motile cells (lamellipodia), thus there is a sub-
stantial possibility that MT1-MMP processes CD44. In this
study, we demonstrated that MT1-MMP directly shed
CD44H from the cell surface and stimulated cell migra-
tion. Identification of the processing sites of CD44H by
MT1-MMP enabled us to design the mutant CD44H that
 
is resistant to the processing. Expression of the mutant
CD44H could not stimulate cell migration and rather
counteracted the cell migration promoted by wild-type
CD44H and MT1-MMP. These results provide a novel
molecular paradigm of cell migration that may be involved
in tumor invasion and metastasis.
 
Materials and Methods
 
Expression Vectors for CD44H, Its 
Mutants, and MT-MMPs
 
The cDNA encoding CD44H was obtained by reverse transcript PCR
(RT-PCR) using total RNA isolated from MIA PaCa-2 cells and sub-
cloned into the mammalian expression vector, pSG5 (Stratagene). The se-
quence was confirmed to be identical to that of accession no. M24915 by
DNA sequencing. The cDNA encoding CD44H, tagged with c-Myc
epitope at the NH
 
2 
 
terminus and with a FLAG tag at the COOH terminus,
was generated by PCR and subcloned into pSG5. A mutant CD44H that
lacks the region between Lys158 to Thr197 (CD44HM), which includes all
MT1-MMP cleavage sites, was constructed by PCR. All the PCR-gener-
ated fragments were confirmed by DNA sequencing. The cDNAs of hu-
man MT1-MMP (accession no. D26512), MT2-MMP (D86331), MT3-
MMP (D50477), MT4-MMP (AB021225), and MT5-MMP (AB021227)
were subcloned into pSG5. (Sequence data are available from GenBank/
EMBL/DDBJ under indicated accession nos.)
 
RT-PCR and Their Primers
 
In brief, total RNA (3 
 
m
 
g) was reverse transcribed with 0.3 
 
m
 
g of random
primer. Then, a portion of reverse transcript product (1 
 
m
 
l) was amplified
with Taq DNA polymerase using a Takara DNA thermal cycler MP
(Takara) for 30 cycles (20 cycles for glyceraldehyde-3-phosphate dehydro-
genase [GAPDH]). Primers for specific amplification were listed as fol-
lows: CD44 (forward primer: 5
 
9
 
-AGACATCTACCCCAGCAAC-3
 
9
 
, re-
verse primer: 5
 
9
 
-CGTTGAGTCCACTTGGCTTTC-3
 
9
 
); MT1-MMP
(forward primer: 5
 
9
 
-GCTTGCAAGTAACAGGCAAA-3
 
9
 
, reverse
primer: 5
 
9
 
-AAATTCTCCGTGTCCATCCA-3
 
9
 
); MT2-MMP (forward
primer: 5
 
9
 
-TCGACGAAGAGACCAAGGAGT-3
 
9
 
, reverse primer: 5
 
9
 
-
CTTGAAGTTGTCAACGTCCT-3
 
9
 
); MT3-MMP (forward primer: 5
 
9
 
-
ATGTGCTACAGTCTGCGGAAC-3
 
9
 
, reverse primer: 5
 
9
 
-TATCCA-
CATCACGTTTGCCA-3
 
9
 
); MT4-MMP (forward primer: 5
 
9
 
-TGCGTG-
CACTCATGTACTAC-3
 
9
 
, reverse primer: 5
 
9
 
-GCCGCATGATGG-
AGTGTGCA-3
 
9
 
); MT5-MMP (forward primer: 5
 
9
 
-GGATCAGACAAC-
GATCGAGT-3
 
9
 
, reverse primer: 5
 
9
 
-CAGCTTGAAGTTGTGCGTCT-
3
 
9
 
); GAPDH (forward primer: 5
 
9
 
-AAGGCTGAGAACGGGAAGCT-
TGTCATCAAT-3
 
9
 
, reverse primer: 5
 
9
 
-TTCCCGTCTAGCTCAGG-
GATGACCTTGCCC-3
 
9
 
).
 
Cell Culture and Transfection of Expression Plasmids
 
Cell lines from human pancreatic carcinoma (MIA PaCa-2), breast carci-
noma (ZR-75-1), and osteosarcoma (MG-63) were obtained from Ameri-
can Type Culture Collection and cultured in RPMI-1640 medium (Life
Technologies) supplemented with 10% FBS and kanamycin.
Cells were seeded in six-well plates at 10
 
5
 
 cells/well and transfected
with plasmid DNA (1 
 
m
 
g) using FuGENE6™ (Roche Molecular Bio-
chemicals) according to the manufacturer’s instructions.
 
Antibodies and Inhibitors
 
Mouse mAb (2C5) against human CD44 was from R&D Systems; anti–
human CD44 rat mAb A020 was from Chemicon International Inc.;
mouse anti-FLAG M2 mAb was from Sigma-Aldrich; mouse anti–c-Myc
mAb was from Oncogene Research Products; and mouse anti–hMT1-
MMP mAb (113-5B7), mouse anti–hMT2-MMP mAb (162-22G5), and
mouse anti–MT3-MMP mAb (117-4E) were gifts from Dr. Kazushi Iwata
(Fuji Chemical Industries, Toyama, Japan). Polyclonal antibodies specific
to MT4-MMP and MT5-MMP were raised in rabbit using recombinant en-
zymes expressed in 
 
Escherichia coli
 
 as antigens. Proteinase inhibitors,
4-(2-Aminoethyl)-benzenesulfonyl fluoride hydrochloride (AEBSF),
 
N
 
-[
 
N
 
-(
 
L
 
-3-Trans-carboxirane-2-carbonyl)-
 
L
 
-leucyl]-agmatine (E-64) and
soybean trypsin inhibitor were purchased from Roche Molecular Bio- 
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chemicals. BB94 (Talbot and Brown, 1996) was a gift from Dr. Peter D.
Brown (British Biotech Pharmaceuticals Ltd., Oxford, UK). Tissue inhibi-
tor of metalloproteinase (TIMP)–1 and TIMP-2 were expressed in High-
Five insect cells (Invitrogen) infected with recombinant baculoviruses to
express human TIMP-1 and TIMP-2, respectively. Recombinant viruses
were made using BAC-TO-BAC™ baculovirus expression systems (Life
Technologies). TIMPs were purified from culture medium by Green A
Dyematrex (Millipore) and gel permeation column on S-200.
 
Western Blot Analysis
 
To detect proteins in the culture supernatant, the medium was treated
with 10% TCA. Cell lysate and TCA-precipitated proteins were separated
by SDS-PAGE, and the proteins in the gel were transferred to a polyvi-
nyldifluoride membrane. After blocking the membrane with 10% fat-free
dry milk in Tris-buffered saline, the membrane was probed with the first
antibody specific to each antigen. The membrane was further probed with
alkaline phosphatase–conjugated goat anti–mouse IgG to visualize bands.
 
Indirect Immunofluorescence Staining
 
Transfected cells were seeded on glass coverslips at 3 
 
3
 
 10
 
4
 
 cells/well. 16 h
later, cells were fixed with 4% paraformaldehyde in PBS (pH 7.5) and
stained with rat anti-hCD44 mAb (A020) and mouse anti–hMT1-MMP
mAb (113-5B7). Cy3-conjugated goat anti–mouse IgG (Jackson Immu-
noResearch Laboratories) and Alexa 488–conjugated goat anti–rat IgG
(Molecular Probes) were used as a secondary antibody. F-Actin was stained
by Alexa 594–conjugated phalloidin (Molecular Probes). The signals were
analyzed using confocal laser microscope (Bio-Rad Laboratories).
 
HA-binding Assay
 
ZR-75-1 cells transfected with the expression plasmids were seeded in a
12-well plate at 3 
 
3
 
 10
 
4
 
 cells/well. 24 h later, the culture medium was re-
placed with serum-free medium containing 100 
 
m
 
g/ml fluorescein-conju-
gated HA (FITC-HA; Seikagaku Kogyo). After a period of incubation at
37
 
8
 
C, the cells were washed three times with PBS, fixed with 4% parafor-
maldehyde, and analyzed by confocal laser microscope. The fluorescence
intensity of the cell-bound HA was measured using LaserSharp processing
software (Bio-Rad Laboratories) and a confocal laser microscope.
 
Expression of rCD44HS and rCD44HSM in E. coli
 
The cDNA encoding stem region of CD44H (
 
130
 
Thr–
 
268
 
Glu), with FLAG
tag at the NH
 
2 
 
terminus and His
 
6
 
 tag at the COOH terminus (rCD44HS),
and its deletion mutant rCD44HSM (deleted between Lys158 and
Thr197) were generated by PCR and subcloned into pET3a expression
vector (Stratagene). All the PCR-generated fragments were confirmed by
DNA sequencing. The 
 
E. coli
 
 strain of BL21 (DE3)pLysS was trans-
formed with these plasmids, and the protein expression was induced by 0.4
mM IPTG. Cells were collected and sonicated in TNC buffer (50 mM
Tris-HCl, 150 mM NaCl, 10 mM CaCl
 
2
 
, 0.02% NaN
 
3
 
) containing 2 mM
PMSF. Supernatant was collected, and the His
 
6
 
-tagged protein was puri-
fied by a chelating sepharose and a gel filtration column using ÄKTA ex-
plorer 10S systems (Amersham Pharmacia Biotech).
 
Determination of the Cleavage Sites of CD44H
 
To determine the cleavage sites of CD44H, purified rCD44HS was incu-
bated with purified active catalytic domain of MT1-MMP in TNC buffer.
The reaction was terminated by addition of EDTA, adjusting final con-
centration at 50 mM. The generated fragments were separated by reverse
phase chromatography on a Sephasil protein C4 5 
 
m
 
m ST 4.6/100 column
(Amersham Pharmacia Biotech) using a linear gradient of 10–40% aceto-
nitrile with 0.1% trifluoroacetic acid by ÄKTA explorer 10S systems
(Amersham Pharmacia Biotech). The NH
 
2
 
-terminal amino acid sequence
of each fragment was determined using the Beckman Coulter LF3000
amino acid sequencer.
 
Phagokinetic Track Motility Assay
 
Phagokinetic track motility assay was performed as described previously
(Albrecht-Buehler, 1977). Colloidal gold-coated coverslips were placed in
a 12-well plate, and transfected cells were seeded at 3 
 
3
 
 10
 
3
 
/well. After
12-h incubation, the phagokinetic tracks were visualized using dark-field
 
illumination in a confocal laser microscope (Bio-Rad Laboratories). Im-
ages were processed and measured using NIH Image software.
 
Results
 
Processing of CD44H by MT-MMPs
 
To examine whether MT-MMPs can shed CD44H,
CD44H was coexpressed with different MT-MMPs in hu-
man breast carcinoma ZR-75-1 cells that express undetect-
able levels of both endogenous CD44H and MT1-MMP.
Expressed CD44H was detected as a 95-kD protein (Fig. 1
A, Cell, lane 2) and did not show soluble fragment
sCD44H in the medium (Med, lane 2). On the other hand,
coexpression of MT1-MMP or MT3-MMP resulted in
shedding of a 70-kD sCD44H into the media (lanes 3 and
5, respectively), whereas MT2, MT4, and MT5-MMP did
not (lanes 4, 6, and 7, respectively). To ensure that the lack
of CD44H processing by MT2, MT4, and MT5-MMP is
not the result of inefficient delivery of the enzymes to the
cell surface, immunoreactivity of FLAG-tagged MT-
MMPs on the surface was examined. Relative intensities
of cell surface signals were as follows: MT1-MMP (1.0);
MT2-MMP (0.32); MT3-MMP (0.36); MT4-MMP (1.08);
MT5-MMP (0.29); and that of mock-transfected cells was
negligible. Thus, the amount of MT2, MT4, and MT5-
MMP on the cell surface is almost comparable to that of
MT3-MMP that can cleave CD44H. The cells also showed
gelatin-degrading activity upon expression of MT-MMPs
in a BB94-sensitive manner (synthetic hydroxamate MMP
inhibitor). Relative gelatin-degrading activities by the cells
were as follows: MT1-MMP (
 
1
 
3), MT2-MMP (
 
1
 
1), MT3-
MMP (
 
1
 
2), MT4-MMP (
 
1
 
1), MT5-MMP (
 
1
 
1).
The shedding by MT1-MMP was inhibited by TIMP-2
and BB94, but not by TIMP-1 or a serine proteinase inhib-
itor, AEBSF (Fig. 1 B). TIMP-2 but not TIMP-1 is known
to inhibit MT1-MMP, whereas all soluble MMPs including
MMP-2 and MMP-13 can be inhibited by both TIMPs (Na-
gase and Woessner, 1999; Seiki, 1999). Also, endogenous
MMP-2 was not detected in the culture supernatant of ZR-
75-1 by zymography (data not shown). Thus, CD44H is
thought to be processed directly by MT1-MMP rather than
by some other soluble MMPs activated by MT1-MMP.
Similar results were obtained with MT3-MMP.
Upon coexpression of either MT1-MMP or MT3-MMP
with CD44H, CD44H with a lower molecular mass (80
kD) was detected in the cell fraction in addition to the 95-
kD CD44H (Fig. 1 A). To examine the integrity of the
NH
 
2
 
- and COOH-terminal ends of the molecule, we con-
structed CD44H, tagged with c-Myc epitope at the NH
 
2
 
terminus and FLAG tag at the COOH terminus, and sub-
jected it to Western Blotting using specific antibodies
against these tags. Consequently, the 80-kD CD44H in the
cell lysate appeared to retain both tags (Fig. 1 C), suggest-
ing that it is not a processing product of 95-kD CD44H
and the polypeptide core is intact. Thus, posttranslational
modifications of CD44H, most likely glycosylations, might
be affected by the coexpression of these MT-MMPs, al-
though the reason is not clear. Also, the 70-kD sCD44H
detected in culture medium was confirmed to be the NH
 
2
 
-
terminal part of CD44HMF retaining the NH
 
2
 
-terminal
Myc tag but not the COOH-terminal FLAG tag (Fig. 1 C). 
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Effect of CD44H Processing on Ligand-binding 
Capacity and Morphology of the Cells
 
HA is the major ligand for CD44 on the cell surface.
Therefore, we examined the effect of processing of
CD44H by MT1-MMP on the ability of the cells to bind
HA. Transfected ZR-75-1 cells were incubated with in-
creasing amount of FITC-HA, and amount of the bound
HA was quantified by fluorescence scanning using a con-
focal laser microscope (Fig. 2 A). The expression of
CD44H greatly increased the binding of FITC-HA com-
pared with the mock-transfected cells. The binding was
saturable, and an addition of 100-fold excess nonlabeled
HA competed the binding and decreased it to the level of
nontransfected cells (Mock). Coexpression of MT1-MMP
with CD44H reduced the HA binding activity significantly
by 40% (Fig. 2 B, compare CD44H
 
1
 
MT1 with CD44H).
On the other hand, when the transfected cells were cul-
tured in the presence of BB94 to inhibit the shedding of
CD44H, the amount of bound HA was significantly in-
creased compared with samples without BB94 (Fig. 2 B,
compare CD44H
 
1
 
MT1/BB94 with CD44H
 
1
 
MT1). Thus,
expression of MT1-MMP surely downregulates the net
HA-binding activity as a result of CD44H processing.
Expression of CD44H in ZR-75-1 significantly altered
cell morphology, possibly by changing the adherent nature
of the cells. As shown in Fig. 2 C, expression of CD44H re-
sulted in the formation of numerous small and large pro-
trusions (arrowheads) at the adherent edge of the cells
compared with the mock-transfected cells (Fig. 2 K).
When MT1-MMP was coexpressed with CD44H, on the
other hand, these protrusions were not formed (Fig. 2, E
and I). The expression of MT1-MMP alone did not change
cell shape (Fig. 2 H) compared with the mock-transfected
cell (Fig. 2 K). The effect of MT1-MMP on the CD44H-
expressing cells (Fig. 2, E and I) appeared to be the result
of CD44H processing by MT1-MMP, as many protrusions
were formed when the cells were cultivated in the pres-
ence of BB94 (Fig. 2, F and J).
 
Effect of CD44H and MT1-MMP on Cell Migration
 
Next, we examined the effect of CD44H and MT1-MMP
on the migration of the cells. As shown in Fig. 3, A and B,
the expression of either CD44H or MT1-MMP alone had
no effect on the cell migration. However, coexpression of
CD44H and MT1-MMP significantly increased motility of
the cells. Addition of BB94 to these transfectants, which
inhibits the processing of CD44H by MT1-MMP (Fig. 1 C),
suppressed the increased cell migration. A similar result
was also obtained with the MG-63 osteosarcoma cell line,
which expresses low levels of CD44H (Fig. 3, C and D).
Since the expression plasmids were introduced into the
cells by transient transfection together with green fluores-
cent protein (GFP) plasmid as a transfection marker, we
could compare motility of both transfected and nontrans-
fected cells in the same field. Stimulation of cell migration
was observed only with the transfected cells expressing
CD44H and MT1-MMP, but not with the surrounding
nontransfected cells, indicating that the shed CD44H frag-
ment itself does not have activity to stimulate cell motility
(Fig. 3 D). We also examined the cell motility using coloi-
dal gold glass coverslips coated with HA instead of serum-
coated coverslips, but there are no differences in the data.
When cell surface localization of both CD44H and
MT1-MMP were analyzed by confocal microscope, both
molecules appeared to distribute over the cell surface (Fig.
Figure 1. Shedding of CD44H by MT-MMPs. (A) CD44H was
coexpressed with each of the MT-MMPs, as indicated by tran-
sient transfection of the expression plasmids into ZR-75-1 cells,
and incubated in the serum-free media. After 48 h, cell lysates
and medium fractions were collected and subjected to Western
Blot analyses using monoclonal anti-CD44 and specific antibod-
ies against each MT-MMP. (B) ZR-75-1 cells were transiently
transfected with the expression plasmids for CD44H and MT1-
MMP and cultured in serum-free media in the presence or ab-
sence of various proteinase inhibitors as indicated. After 48 h,
cell lysates and medium fractions were collected and subjected to
Western blot analyses. (C) CD44H with NH2-terminal c-Myc tag
and COOH-terminal FLAG tag was coexpressed with each of
the MT-MMPs, as indicated by transient transfection of the ex-
pression plasmids into ZR-75-1 cells, and analyzed the same as in
A. The antibody against FLAG and c-Myc were used to deter-
mine the integrity of the peptide core of CD44H for the Western
blot as indicated. 
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3 E, Integrated Image). However, colocalization was
prominent at the adherent edge of the transfected cells
(Fig. 3 E, Adherent Layer).
 
Determination of the Cleavage Site 
of CD44H by MT1-MMP
 
According to the molecular size of sCD44H, the cleavage
site of CD44H by MT1-MMP was expected to locate within
the stem region of CD44H (Thr130-Gln265) that is be-
tween the globular and transmembrane domain (Fig. 4 A).
Therefore, we expressed the fragment corresponding to
that region (rCD44HS) in 
 
E. coli
 
 and incubated it with
recombinant MT1-MMP catalytic domain (rMT1-CAT)
 
to determine the putative cleavage site. Incubation of
rCD44HS with rMT1-CAT generated 28- and 26-kD bands
in a time-dependent manner on SDS-PAGE (data not
shown). To isolate these fragments, the reaction mixture
was subjected to reverse phase chromatography, and four
fragment peaks were recovered (Fig. 4 B). These peak frac-
tions were collected and subjected to NH
 
2
 
-terminal amino
acid sequence analyses. The NH
 
2
 
-terminal sequence of
peak 2 corresponded to that of the original fragment, and
those of peaks 1, 3, and 4 were mapped to 
 
163
 
Thr (TNPED),
 
193
 
Tyr (YIFYT), and 
 
187
 
Ser (SSTSG), respectively (Fig. 4
C). From their molecular sizes and height of the peaks,
cleavage between the Gly
 
192
 
–Tyr bond (corresponding to
peak 3) and Arg
 
186
 
–Ser bond (corresponding to peak 4) are
Figure 2. Effect of CD44
shedding on HA-binding ac-
tivity and cell morphology.
(A) ZR-75-1 cells were trans-
fected with expression plas-
mid for CD44. After 24 h, the
cells were incubated with in-
creasing concentrations of
FITC-labeled HA for 60 min
at 378C. After washing un-
bound FITC-HA, the relative
intensity of green fluores-
cence of the transfected cells
was analyzed by confocal la-
ser microscopy. The average
value of 40 individual cells
was plotted (mean 6 SEM).
A 100-fold excess amount of
cold-HA was used to compete
FITC-HA binding. (B) ZR-
75-1 cells were transfected
with expression plasmids for
CD44 and/or MT1-MMP.
FITC-HA binding was ana-
lyzed similarly. ZR-75-1 cells
were transfected with control
vector (Mock), CD44H
cDNA (CD44H), CD44H
and MT1-MMP cDNAs
(CD44H1MT1), CD44H and
MT1-MMP cDNAs cul-
tured in the presence of
BB94 (CD44H1MT1/BB94).
(C–K) ZR-75-1 cells trans-
fected with expression plas-
mids indicated were cultured
on glass slides. The cells were
stained with rat anti–human
CD44 and mouse anti–human
MT1-MMP mAbs without
permeabilization. Signals
were visualized by further
probing with Alexa 488–con-
jugated anti–rat IgG or Cy3-
conjugated anti–mouse IgG
and analyzed by a confocal
laser microscope. Represen-
tative pictures are pre-
sented. Cells express CD44H (C and G), MT1-MMP (D and H), CD44H and MT1-MMP (E and I), CD44H and MT1-MMP cultured in
the presence of BB94 (F and J), and mock-transfected cells (K). Cells were stained with ant-CD44 mAb (C–F) or anti–MT1-MMP
(G–J). Mock cells were stained for F-actin by Cy3-conjugated phalloidin (K). *P , 0.05 by Student’s t test. 
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likely to generate 26- and 28-kD fragments, respectively. A
mutant CD44H fragment that lacks the 40 internal amino
acids, which include all the three cleavage sites (
 
158
 
Lys to
 
197
 
Thr), was constructed, and it was confirmed to be resis-
tant to cleavage by rMT1-CAT (data not shown).
 
CD44H Processing Is Critical for Cell Migration
 
Although BB94 inhibits cell migration driven by CD44H
and MT1-MMP, it does not necessarily mean that the pro-
cessing of CD44H is the absolute requirement for cell mi-
gration. To examine this, we constructed the mutant
CD44H that can not be processed by MT1-MMP. Deletion
of the 40 internal amino acids (
 
158
 
Lys–
 
197
 
Thr) was intro-
duced into CD44H (Fig. 4 A, CD44HM), and it was ex-
pressed in ZR-75-1 cells. CD44HM was not shed by MT1-
MMP under the condition where the wild-type CD44H was
shed into the media (Fig. 5 A). To confirm that the mutant
CD44HM retains comparable ligand-binding ability to the
wild-type CD44H, binding of FITC-HA to the cells was ana-
 
lyzed. The cells expressing CD44HM showed comparable
HA-binding activity (Fig. 5 D) and similar morphological
change of the cells to that of the wild-type CD44H-express-
ing cells (Fig. 5, B and C). On the other hand, coexpression
of MT1-MMP with CD44HM did not promote migration
of the cells (Fig. 5 E, CD44HM
 
1
 
MT1). Furthermore,
CD44HM inhibited migration of the cells promoted by
CD44H and MT1-MMP (Fig. 5 E, compare CD44H
 
1
 
CD44HM
 
1
 
MT1 with CD44H
 
1
 
MT1), suggesting a domi-
nant-negative effect against the wild-type CD44H. These
data indicate that processing of CD44H is an essential step
for CD44H and MT1-MMP–promoted cell migration.
 
Proteinases Responsible for CD44H Shedding 
in a Human Pancreatic Tumor Cell Line
 
A human pancreatic tumor cell line, MIA PaCa-2, ex-
presses high levels of CD44, which is spontaneously shed
into the culture medium (Fig. 6 A). The major form of
CD44 expressed in MIA PaCa-2 cells was confirmed to be
Figure 3. Effect of the shed-
ding of CD44H by MT1-
MMP on the cell motility. (A)
ZR-75-1 cells were trans-
fected with the expression
plasmids for CD44H and/or
MT1-MMP together with the
one for GFP. The motility of
GFP-positive cells was ana-
lyzed by phagokinetic track
assay on colloidal gold–coated
coverslips. The migrated area
of the cell was visualized un-
der darkfield illumination,
and migration area was mea-
sured using NIH Image. The
average of 30 cells 6 SEM is
shown. (B) Representative
phagokinetic track of the mi-
grating cell was visualized
under darkfield illumination
(Refraction). Transfected
cells were indicated as GFP-
positive cells (GFP). (C)
Osteosarcoma MG-63 cells
were analyzed as above. (D)
Representative phagokinetic
track of the migrating cell
was visualized under dark-
field illumination (Refrac-
tion). Transfected cells were
indicated as GFP-positive
cells (GFP). (E) MT1-MMP
and CD44H expressing ZR-
75-1 cells on glass coverslip
were immunostained for
CD44H and MT1-MMP. The
signal was analyzed by confo-
cal microscope. The com-
bined image from all sections
(top, Combined Sections)
and one section from the cell
attachment site is shown
(bottom, Adherent Section).
*P , 0.05 by Student’s t test. 
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CD44H by RT-PCR using a set of specific primers that can
amplify all the splicing variants (Fig. 6 B).
Using an anti-CD44 mAb, 95-kD CD44H was detected
in the cell lysate as a major form (Fig. 6 A, lane 1). The cells
shed 90- and 70-kD sCD44H spontaneously into the me-
dium (Fig. 6 A, lane 1). To examine the types of proteinases
that are responsible for the shedding, we tested proteinase
inhibitors selective for metalloproteinase (BB94), serine
proteinases (AEBSF), and cystein proteinases (E-64) (Fig.
6 A). BB94 completely inhibited the shedding of the 70-kD
fragment, selectively (Fig. 6 A, lane 5). In contrast, AEBSF
inhibited the shedding of the 90-kD but not the 70-kD frag-
 
ment (Fig. 6 A, lane 7). The combination of BB94 and
AEBSF inhibited the shedding of the both fragments (Fig.
6 A, lane 8). Thus, the 70-kD fragment is processed by me-
talloproteinases, and the 90-kD fragment, by serine protein-
ases. Since inhibition of serine poroteinase did not inhibit
the shedding of the 70-kD form, the shedding event by
these different types of proteinase occurred independently
rather than in a sequential manner. The shedding of the 70-
kD fragment was inhibited by TIMP-2 but not by TIMP-1
(Fig. 6 A, lanes 2 and 3) and the size of the fragment is sim-
ilar to that of the one processed by MT1-MMP upon coex-
pression with CD44H. Such different sensitivity to TIMP-1
and TIMP-2 is characteristic of MT-MMPs (Nagase and
Woessner, 1999; Seiki, 1999). Thus, the metalloproteinase
responsible for the shedding of the 70-kD fragment in MIA
PaCa-2 cells is likely to be either MT1-MMP or MT3-MMP
as they have the ability to process CD44H (Fig. 1). Tran-
scripts for MT-MMPs were analyzed by RT-PCR, and MIA
Paca-2 cells were found to express MT1-MMP but not
MT3-MMP (Fig. 6 B). Expression of MT1-MMP was also
confirmed by Western blotting (data not shown).
 
Processing Site–deleted Mutant, CD44HM, Inhibits 
Migration of the Pancreatic Tumor Cells
 
MIA PaCa-2 cells showed spontaneous motile activity on
the slide glass coated with coloidal gold (see below). Thus,
we asked whether this motility is attributed to the shed-
ding of endogenous CD44H by MT1-MMP (Fig. 7, A and
B). BB94, which inhibits shedding of 70-kD sCD44H, sup-
pressed the motility by 65%, whereas the serine proteinase
inhibitor (trypsin inhibitor) had no effect. In addition, ex-
pression of CD44HM inhibited the motility by 40%,
whereas expression of full-length CD44H had no effect.
Since CD44HM plasmid was transfected transiently, both
transfected and nontransfected cells were found in the
same field (transfected cells with arrow). In spite of the
spontaneous shedding of 70 kD sCD44 from surrounding
cells, inhibition of the motility was observed with the cells
expressing CD44HM (Fig. 7 B, CD44HM). This suggests
that processing event but not its product (70-kD sCD44) is
important to promote migration.
CD44HM is resistant to MT1-MMP–dependent process-
ing but still susceptible to the serine proteinase, as it was
shed as a 78-kD fragment that was inhibited by AEBSF
(data not shown) or trypsin inhibitor (Fig. 7 C, lane 4).
Since CD44HM inhibited the migration of the cells, this
further strengthened the idea that MT1-MMP–dependent
shedding of CD44H promotes cell migration, whereas the
shedding by a serine proteinase has no effect on the motile
phenotype of the cells.
Discussion
Processing of ECM Receptors and Cell Migration
Organized ECM–cell interaction is essential for cell migra-
tion (Keely et al., 1998; Sheetz et al., 1998), and CD44 is
one of the ECM receptors that is thought to mediate cell
migration (Naot et al., 1997; Sneath and Mangham, 1998;
Bourguignon et al., 2000). CD44 is a primary receptor for
HA, which is abundantly present in many tissue (Naot et
al., 1997). However, such interaction itself may limit cell
Figure 4. Processing of CD44H by MT1-MMP in vitro. (A)
Schematic illustration of CD44H, the stem fragment (rCD44HS)
expressed in E. coli, and the mutant lacking the processing sites
by MT1-MMP (CD44HM). Fragments expressed in E. coli were
tagged with FLAG at the NH2 terminus and His6 at the COOH
terminus, as indicated. Processing sites (C) are indicated by the
arrowheads. (B) rCD44HS (96 mg) was incubated with 3.6 mg of
the catalytic fragment of MT1-MMP (rMT1CD) at 378C for 180
min. Reaction products were separated by reverse-phase chro-
matography. Peaks indicated (peaks 1–4) were collected and sub-
jected to automatic amino acid sequencer (Beckman Coulter
LF3000). (C) Amino acid sequence of rCD44HS is presented.
Thick letters at the NH2 terminus are the FLAG tag, and those at
the COOH terminus are the His6 tag. The sequence between the
tags corresponds to T130-E268 of CD44H. The determined NH2-
terminal sequences of the peaks are underlined. Stem, the region
between the HA-binding globular domain and transmembrane
domain; TM, transmembrane domain; CP, cytoplasmic tail.The Journal of Cell Biology, Volume 153, 2001 900
movement in tissue. In addition, CD44 binds other solid
ECM components such as collagen I or fibrin as well
(Naot et al., 1997). Therefore, it appears critical to regu-
late detachment and attachment in an organized manner
in order to accomplish cell migration
In this study, we demonstrated that CD44H stimulated
cell migration when it is coexpressed with MT1-MMP.
This phenomenon was accompanied by the shedding of
CD44H from the cell surface by MT1-MMP. Although the
precise mechanism to stimulate the cell motility is still un-
known, the shedding event appears to be important, as the
expression of the mutant CD44HM that can not be pro-
cessed by MT1-MMP did not stimulate the migration (Fig.
5 E). It is possible to speculate that the shed 70-kD frag-
ment stimulates cell motility in an autocrine and paracrine
manner. However, this is not plausible because the effect
of CD44H and MT1-MMP was not observed with the sur-
rounding nontransfected cells in the same field (Fig. 3 D).
In addition, expression of CD44HM suppressed motility of
the transfected MIA PaCa-2 cells, however the surround-
ing nontransfected cells continuously generate the 70-kD
fragment (Fig. 7 B). There are two possible mechanisms
for the promotion of cell migration. One is that cleavage of
CD44H by MT1-MMP may be required for the cells to de-
tach from the ECM to migrate, and the other is that the
COOH-terminal portion of the fragment remaining on the
cell may generate some signals to stimulate motility. We
prefer the former possibility because CD44HM acted
dominant negatively against the wild-type CD44H in the
cells expressing MT1-MMP (Fig. 5). It is interesting that
an unknown serine proteinase also processes CD44H, but
this shedding exerts no effect on the cell motility. These
results may indicate that the processing of CD44H by two
proteinase systems is regulated independently in space
and timing. Although we do not know the localization of
the serine proteinase, it may be different from that of
MT1-MMP. CD44H is concentrated at the adherent edge,
together with MT1-MMP, but it also distributes over the
surface of the cells (Fig. 3 E). Thus, we prefer the idea that
spatial and timely processing of CD44H at the adherent
edge by MT1-MMP is critical for stimulation of the migra-
tion, allowing cells to be detached from the ECM to move
on to the different site. Alternatively, shedding of CD44H
by a serine proteinase may occur on the cell body where
CD44H is not interacting with the foothold ECM. Al-
though many reports have shown that expression of CD44
promotes cell migration (Thomas et al., 1992, 1993; Henke
et al., 1996; Okada et al., 1996; Trochon et al., 1996;
Ladeda et al., 1998), the mechanisms that explain this phe-
nomenon have been obscure. This is the first report to our
knowledge that discloses the specific molecular interaction
underlying this phenomenon.
Recombinant CD44H fragment was processed by MT1-
MMP at three sites. However, the fragment produced in E.
coli lacks glycosylations that may affect accessibility of the
enzyme. Thus, there is a possibility that processing sites on
the cell surface may differ from these sites determined in
vitro. If CD44H (95 kD) on the cell surface is cleaved at
Figure 5. Dominant-negative
effect of CD44HM on cell mi-
gration stimulated by CD44H
and MT1-MMP. (A) Either
wild-type CD44H or the mutant
CD44HM was expressed in ZR-
75-1 cells together with MT1-
MMP. Cell lysate and medium
fractions were subjected to
Western blot analyses as de-
scribed in the legend to Fig.
2. (B and C) CD44H- or
CD44HM-expressing ZR-75-1
cells were stained with rat anti–
human CD44 mAb and analyzed
by confocal microscopy. (D)
HA-binding activity of CD44H-
or CD44HM-expressing ZR-75-1
were examined as described in
the legend to Fig. 2. Transfected
cells were incubated with FITC-
HA for 3 h at 378C, and fluores-
cence associated to the cells was
measured. (E) Transfected ZR-
75-1 cells were subjected to the
migration assay as described in
the legend to Fig. 3. *P , 0.05
by Student’s t test.Kajita et al. CD44 Processing by MT1-MMP 901
these three sites, expected molecular mass of the sCD44H
would be 73–76 kD, which is close to the 70-kD fragment
we observed. However, due to heterogeneous glycosyla-
tion of the molecule, we could not confirm that the 70-kD
fragment contains three different cleavage products. Nev-
ertheless, we think that the actual cutting site by MT1-
MMP contains at least one of the identified sites because
deletion mutant CD44HM was not processed.
The role of CD44H during cell migration may resemble
that of L-selectin during leukocyte rolling on endothelial
cells. At the early stage of inflammation, circulating neutro-
phils start to interact with endothelial cells, and then ex-
Figure 6. Shedding of endoge-
nous CD44H in human pancre-
atic tumor cell line, MIA PaCa-2.
(A) MIA PaCa-2 cells (3 3 105)
were cultured in a six-well plate
in serum-free medium in the
presence or absence of the pro-
teinase inhibitors as indicated.
After 48 h, the cell lysate (bot-
tom) and the conditioned me-
dium (top) were subjected to
Western blot analyses. CD44 was
detected by the mouse anti–
human CD44 mAb. Concentra-
tions of the inhibitors were ad-
justed as follows: 50 nM for
TIMP-1, 50 nM for TIMP-2, 10
mM for BB94, 1.0 mM for E-64,
and 1.0 mM for AEBSF. (B) Ex-
pression of genes for CD44 and MT-MMPs were examined by RT-PCR using specific primers as described in Materials and Methods. Sizes
of the amplified fragments were 461 bp for CD44, 589 bp for MT1-MMP, 578 bp for MT2-MMP, 461 bp for MT3-MMP, 334 bp for MT4-
MMP, 564 bp for MT5-MMP, and 500 bp for GAPDH. PCR product of CD44 indicates that CD44 expressed in MIA PaCa-2 is CD44H.
Figure 7. BB94 and
CD44HM inhibits motile ac-
tivity of MIA PaCa-2. (A)
MIA PaCa-2 cells were trans-
fected with the expression
plasmid for the FLAG-
tagged CD44H or CD44HM
together with the one for
GFP. After 48 h, cells were
subjected to the migration as-
say as described in the leg-
end to Fig. 4. Mock- or
CD44HM-transfected cells
were cultured in the presence
or absence of BB94 or
trypsin inhibitor. (B) Repre-
sentative phagokinetic track
of the migrating cell was visu-
alized under darkfield illumi-
nation (Refraction). Trans-
fected cells were indicated as
GFP-positive cells (GFP; ar-
row). (C) Medium fractions
from same transfectants were
subjected to Western blot
analyses using anti-FLAG
M2 mAb as described in the
legend to Fig. 1. *P , 0.05 by
Student’s t test.The Journal of Cell Biology, Volume 153, 2001 902
travasate to the site of inflammation (Lasky, 1992). The in-
teraction occurs by two steps. First, there is a loose
interaction through cell surface carbohydrates and their re-
ceptors such as L-, E- and P-selectins. Then, tighter interac-
tion mediated by VLA4 and VCAM-1 follows (Ebnet and
Vestweber, 1999). Recently, L-selectin was reported to be
processed by TIMP-3–sensitive metalloproteinases (Bor-
land et al., 1999). In the presence of metalloproteinase in-
hibitor, processing of L-selectin and leukocyte rolling were
inhibited (Walcheck et al., 1996). Both CD44 and L-selec-
tin are the receptors for carbohydrates and play a role in
cell adhesion collaborating with integrins. Thus, coopera-
tion of carbohydrate receptors and integrins may be a gen-
eral apparatus for cell adhesion during migration. It is
known that integrin-dependent adhesion can be released
by intracellular signals (Kolanus and Seed, 1997; Kumar,
1998). On the other hand, the adhesion through carbohy-
drate receptor including CD44 and L-selectin may require
extracellular processing by specific proteinases for the de-
tachment.
A New Role of MT1-MMP in Tumor Invasion
MT1-MMP was originally identified as an activator of
proMMP-2 on the surface of invasive tumor cells (Sato et
al., 1994). MMP-2 is thought to be responsible for the deg-
radation of basement membrane as it degrades type IV
collagen (Liotta et al., 1991; Stetler-Stevenson et al., 1993;
Tryggvason et al., 1993). The rate of activation of MMP-2
in tumor tissue is well-correlated to the expression levels
of MT1-MMP and to the tumor spread (Nomura et al.,
1995; Tokuraku et al., 1995; Nakamura et al., 1999), thus
MT1-MMP is believed to be the in vivo proMMP-2 activa-
tor during cancer cell invasion. MT1-MMP also activates
proMMP-13 (Knauper et al., 1996), and directly degrades
type I, II, and III collagens, fibronectin, vitronectin (Ohu-
chi et al., 1997), and laminin 1 (Ohuchi et al., 1997) and 5
(Koshikawa et al., 2000). Recently, it was shown that peri-
cellular collgen I degrading activity of MT1-MMP ex-
pressed in MDCK cells was shown to be pronounced to ef-
fect on cellular invasiveness, whereas overexpression of
soluble collagenases (MMP-1 and MMP-13) did not affect
it at all (Hotary et al., 2000). It was also reported that the
specific processing of laminin 5 g chain by MT1-MMP it-
self or MMP-2 activated by MT1-MMP stimulated motility
of the breast cancer cells cultured on a laminin 5–coated
dish (Koshikawa et al., 2000). Thus, MT1-MMP is in fact a
powerful tool for cancer cells to migrate through basement
membrane and the interstitial stromal tissue by triggering
direct as well as indirect ECM proteolysis on the cell sur-
face (Basbaum and Werb, 1996; Seiki, 1999).
In addition to the previous knowledge, we demonstrate
here a new role of MT1-MMP in cell migration in conjunc-
tion with CD44H. MT1-MMP is frequently expressed in a
variety of human cancers (Seiki, 1999) and is the major
type of MT-MMP expressed in tumors (Ueno et al., 1997;
Nakamura et al., 1999). CD44H is also expressed fre-
quently and abundantly in human cancer cells (Naot et al.,
1997). Thus, there is a substantial chance for the molecular
cooperation between MT1-MMP and CD44H in cancer
cells, as demonstrated by the pancreatic cancer cell line,
MIA PaCa-2 in this work.
Processing Enzymes for CD44
Although CD44 was reported to be shed by both serine
proteases and metalloproteinase (Bazil and Strominger,
1994, Okamoto et al., 1999), little was known about the
responsive proteases and the shed fragments. In this re-
port, we demonstrated that CD44H can be shed as a 90-
kD fragment by unknown serine proteinases and a 70-kD
fragment by MT1-MMP in MIA PaCa-2 cells. Although
the 70-kD CD44H fragment can be shed by MT1-MMP,
MT1-MMP may not be the only enzyme to generate the
70-kD fragment in other cells. Indeed, another pancre-
atic tumor cell line, PANC-1, expresses very low levels of
MT1-MMP, but the level of shed 70-kD sCD44H was
similar to that of MIA-PaCa 2. In PANC-1, the shedding
was inhibited by TIMP-1, which cannot inhibit MT1-
MMP (data not shown). Okamoto et al. (1999) also re-
ported CD44 shedding by unknown TIMP-1-sensitive
metalloproteinase in U251MG human glioma cells. Thus,
there is a possibility that some soluble MMPs or ADAM
family member(s) cleave CD44 at similar sites to those
by MT1-MMP in these cell lines. We examined whether
MMP-2, MMP-7, and MMP-9 could digest the rCD44HS
in vitro, however none of these cleaved the fragment
(data not shown). It is interesting that MMP-9 could not
process the fragment, as it is reported to associate with
CD44 (Bourguignon et al., 1998; Yu and Stamenkovic,
1999).
The processing of CD44H by MT1-MMP occurs imme-
diately upstream of the insertion site for variable regions
by alternative splicing, and therefore the efficiency of the
processing may be affected by these insertions. Since bio-
logical activities of these variants have been reported to
vary (Gunthert et al., 1991), it is of interest to consider
how the processing and its effect on migration are affected
by the insertions. Bartolazzi et al. (1995) demonstrated
that CD44 splice variants that contain variable exons 6–10,
7–10, and 8–10 are shed more efficiently than the standard
form in malignant lymphoma cells. Although the type of
responsible proteinase in this case is not known, we are
now investigating the effect of different variant forms of
CD44 on cell migration.
In conclusion, our study shows a novel molecular in-
teraction between CD44H and MT1-MMP that pro-
motes cell migration. Since CD44 and MT1-MMP are
frequently expressed in motile cells, including many
cancer cells, this may be a part of general mechanism
for cell migration and invasion in the tissue. Therefore,
the dominant-negative CD44H (CD44HM) may be-
come a potential tool to treat cancer cell invasion and
metastasis.
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